Triple-Drug cocktail targets Hard-to-Treat blood cancers
NCT ID NCT07679334
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase I trial is testing whether combining three drugs—pacritinib, venetoclax, and azacitidine—is safe and tolerable for people with accelerated or blast phase myeloproliferative neoplasms, aggressive blood cancers. The study enrolls about 20 adults whose disease has progressed beyond earlier stages. Researchers aim to find the best dose of pacritinib when used with the other two drugs, while monitoring side effects.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Pacritinib, venetoclax, and azacitidine
What this could lead to
If safe and effective, this combination could offer a new treatment option for people with advanced myeloproliferative neoplasms, potentially slowing disease progression.
What could go wrong
This is an early phase I trial with only 20 participants, so the main goal is safety and dosing, not proof of effectiveness. Side effects from the drug combination are unknown and could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELOPROLIFERATIVE NEOPLASM are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Roswell Park Comprehensive Cancer Center
Buffalo, New York, 14263, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact